• Je něco špatně v tomto záznamu ?

The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes

K. Seborova, A. Kloudova-Spalenkova, K. Koucka, P. Holy, M. Ehrlichova, C. Wang, I. Ojima, I. Voleska, P. Daniel, K. Balusikova, M. Jelinek, J. Kovar, L. Rob, M. Hruda, M. Mrhalova, P. Soucek, R. Vaclavikova

. 2021 ; 23 (1) : . [pub] 20211222

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011654

Grantová podpora
19-03063S Czech Science Foundation
NU20-09-00174 Czech Health Research Council
PROGRES Q28 Charles University
INTER-COST, LTC19020 Czech Ministry of Education, Youth and Sports
R01 CA103314 NIH HHS - United States

The main problem precluding successful therapy with conventional taxanes is de novo or acquired resistance to taxanes. Therefore, novel experimental taxane derivatives (Stony Brook taxanes; SB-Ts) are synthesized and tested as potential drugs against resistant solid tumors. Recently, we reported alterations in ABCC3, CPS1, and TRIP6 gene expression in a breast cancer cell line resistant to paclitaxel. The present study aimed to investigate gene expression changes of these three candidate molecules in the highly resistant ovarian carcinoma cells in vitro and corresponding in vivo models treated with paclitaxel and new experimental Stony Brook taxanes of the third generation (SB-T-121605 and SB-T-121606). We also addressed their prognostic meaning in ovarian carcinoma patients treated with taxanes. We estimated and observed changes in mRNA and protein profiles of ABCC3, CPS1, and TRIP6 in resistant and sensitive ovarian cancer cells and after the treatment of resistant ovarian cancer models with paclitaxel and Stony Brook taxanes in vitro and in vivo. Combining Stony Brook taxanes with paclitaxel caused downregulation of CPS1 in the paclitaxel-resistant mouse xenograft tumor model in vivo. Moreover, CPS1 overexpression seems to play a role of a prognostic biomarker of epithelial ovarian carcinoma patients' poor survival. ABCC3 was overexpressed in EOC tumors, but after the treatment with taxanes, its up-regulation disappeared. Based on our results, we can suggest ABCC3 and CPS1 for further investigations as potential therapeutic targets in human cancers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011654
003      
CZ-PrNML
005      
20220506130920.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms23010073 $2 doi
035    __
$a (PubMed)35008510
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Seborova, Karolina $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic $1 https://orcid.org/0000000289252321
245    14
$a The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes / $c K. Seborova, A. Kloudova-Spalenkova, K. Koucka, P. Holy, M. Ehrlichova, C. Wang, I. Ojima, I. Voleska, P. Daniel, K. Balusikova, M. Jelinek, J. Kovar, L. Rob, M. Hruda, M. Mrhalova, P. Soucek, R. Vaclavikova
520    9_
$a The main problem precluding successful therapy with conventional taxanes is de novo or acquired resistance to taxanes. Therefore, novel experimental taxane derivatives (Stony Brook taxanes; SB-Ts) are synthesized and tested as potential drugs against resistant solid tumors. Recently, we reported alterations in ABCC3, CPS1, and TRIP6 gene expression in a breast cancer cell line resistant to paclitaxel. The present study aimed to investigate gene expression changes of these three candidate molecules in the highly resistant ovarian carcinoma cells in vitro and corresponding in vivo models treated with paclitaxel and new experimental Stony Brook taxanes of the third generation (SB-T-121605 and SB-T-121606). We also addressed their prognostic meaning in ovarian carcinoma patients treated with taxanes. We estimated and observed changes in mRNA and protein profiles of ABCC3, CPS1, and TRIP6 in resistant and sensitive ovarian cancer cells and after the treatment of resistant ovarian cancer models with paclitaxel and Stony Brook taxanes in vitro and in vivo. Combining Stony Brook taxanes with paclitaxel caused downregulation of CPS1 in the paclitaxel-resistant mouse xenograft tumor model in vivo. Moreover, CPS1 overexpression seems to play a role of a prognostic biomarker of epithelial ovarian carcinoma patients' poor survival. ABCC3 was overexpressed in EOC tumors, but after the treatment with taxanes, its up-regulation disappeared. Based on our results, we can suggest ABCC3 and CPS1 for further investigations as potential therapeutic targets in human cancers.
650    _2
$a adaptorové proteiny signální transdukční $x genetika $7 D048868
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a karbamoylfosfátsynthasa (amoniak) $x genetika $7 D002222
650    _2
$a epiteliální ovariální karcinom $x farmakoterapie $x genetika $7 D000077216
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $x genetika $7 D002470
650    _2
$a down regulace $x účinky léků $x genetika $7 D015536
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a proteiny s doménou LIM $x genetika $7 D060588
650    _2
$a myši $7 D051379
650    _2
$a myši nahé $7 D008819
650    _2
$a lidé středního věku $7 D008875
650    _2
$a proteiny spojené s mnohočetnou rezistencí k lékům $x genetika $7 D027425
650    _2
$a nádory vaječníků $x farmakoterapie $x genetika $7 D010051
650    _2
$a paclitaxel $x terapeutické užití $7 D017239
650    _2
$a taxoidy $x terapeutické užití $7 D043823
650    _2
$a transkripční faktory $x genetika $7 D014157
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kloudova-Spalenkova, Alzbeta $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
700    1_
$a Koucka, Kamila $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Holy, Petr $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/0000000269505563
700    1_
$a Ehrlichova, Marie $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Wang, Changwei $u Institute of Chemical Biology & Drug Discovery, Stony Brook University-State University of New York, Stony Brook, NY 11794, USA
700    1_
$a Ojima, Iwao $u Institute of Chemical Biology & Drug Discovery, Stony Brook University-State University of New York, Stony Brook, NY 11794, USA
700    1_
$a Voleska, Iveta $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic
700    1_
$a Daniel, Petr $u Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/0000000255234184
700    1_
$a Balusikova, Kamila $u Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/0000000204715877
700    1_
$a Jelinek, Michael $u Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
700    1_
$a Kovar, Jan $u Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/0000000194328960 $7 jn20040114001
700    1_
$a Rob, Lukas $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
700    1_
$a Hruda, Martin $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
700    1_
$a Mrhalova, Marcela $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, 150 06 Prague, Czech Republic
700    1_
$a Soucek, Pavel $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic $1 https://orcid.org/0000000242946799 $7 xx0060511
700    1_
$a Vaclavikova, Radka $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine, Charles University, 323 00 Pilsen, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 1 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35008510 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130912 $b ABA008
999    __
$a ok $b bmc $g 1789322 $s 1162852
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 1 $e 20211222 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 19-03063S $p Czech Science Foundation
GRA    __
$a NU20-09-00174 $p Czech Health Research Council
GRA    __
$a PROGRES Q28 $p Charles University
GRA    __
$a INTER-COST, LTC19020 $p Czech Ministry of Education, Youth and Sports
GRA    __
$a R01 CA103314 $p NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace